Lifeward Ltd. (LFWD)
NASDAQ: LFWD · Real-Time Price · USD
0.7930
+0.0089 (1.14%)
At close: Jul 23, 2025, 4:00 PM
0.7900
-0.0030 (-0.38%)
After-hours: Jul 23, 2025, 7:58 PM EDT
Lifeward Revenue
Lifeward had revenue of $5.03M in the quarter ending March 31, 2025, a decrease of -4.71%. This brings the company's revenue in the last twelve months to $25.41M, up 41.92% year-over-year. In the year 2024, Lifeward had annual revenue of $25.66M with 85.24% growth.
Revenue (ttm)
$25.41M
Revenue Growth
+41.92%
P/S Ratio
0.28
Revenue / Employee
$317,675
Employees
80
Market Cap
12.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.66M | 11.81M | 85.24% |
| Dec 31, 2023 | 13.85M | 8.34M | 151.39% |
| Dec 31, 2022 | 5.51M | -455.00K | -7.63% |
| Dec 31, 2021 | 5.97M | 1.57M | 35.81% |
| Dec 31, 2020 | 4.39M | -480.00K | -9.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| Novartis AG | 55.19B |
| AstraZeneca | 54.98B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
LFWD News
- 16 days ago - MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion - PRNewsWire
- 27 days ago - Lifeward Announces Closing of $2.6 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Lifeward Announces Pricing of $2.6 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Administrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary - GlobeNewsWire
- 2 months ago - Lifeward Names Mark Grant as New CEO - GlobeNewsWire
- 2 months ago - Lifeward to Present at Sidoti Virtual Investor Conference on May 21 - GlobeNewsWire
- 2 months ago - Lifeward Ltd. (LFWD) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Lifeward Ltd. Reports First Quarter 2025 Financial Results - GlobeNewsWire